Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, and Merck Sharp & Dohme Corp.

Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?

Release Date: July 31, 2018
Expiration Date: July 31, 2019
Media: Internet - based
 

Activity Overview

Recent advances have been made in diagnosing and treating triple-negative breast cancer (TNBC). It can be difficult for practicing clinicians to stay current with these emerging data. Through a combination of didactic presentations and interactive discussions, our distinguished panel discusses the challenges involved in the management of TNBC. The panel also provides their insights and perspectives on recent clinical studies and investigational approaches for treatment of TNBC, including sequencing strategies for existing and novel agents and combination therapies.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, and Merck Sharp & Dohme Corp.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational activity is directed toward medical oncologists, gynecologic oncologists, and fellows who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

Upon successful completion of this educational program, participants should be better prepared to:

  • Discuss the biology of triple-negative breast cancer (TNBC) in the context of standard approaches and unmet clinical needs in the field
  • Explain novel mechanistic approaches under investigation for the treatment of patients with TNBC 
  • Detail current and emerging clinical trial information concerning the use of chemotherapeutic, targeted, and immunotherapeutic approaches to care for patients with TNBC
  • Evaluate recent clinical trial findings and place them in the context of unmet clinical needs, evolving treatment paradigms in the field, and the need for participation in clinical trials evaluating novel TNBC management strategies

Faculty, Staff, and Planners' Disclosure

Moderator

Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
Co-Chair, Breast Cancer Research Program
The US Oncology Network
Dallas, TX

Disclosure: Consultant: AstraZeneca, Novartis, Lilly; Speakers Bureau: AstraZeneca, Lilly

Faculty

Tiffany A. Traina, MD
Clinical Director, Breast Medicine Service
Section Head, Triple Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
Assistant Professor
Weill Cornell Medical College
New York, NY

Disclosure: Consultant: Genentech/Roche, Eisai, Medivation, Pfizer, AstraZeneca, Merck, Astellas Pharma, Puma Biotechnology, Advaxis, Celgene, Innocrin Pharma, Genomic Health, Bristol-Myers Squibb, Samsung; Speakers Bureau: Roche/Genentech; Research Funding: Medivation, Eisai, Pfizer, Novartis, Innocrin Pharma, AstraZeneca, Astellas Pharma

Charles Shapiro, MD
Professor of Medicine
Director, Translational Breast Cancer Research
Director, Survivorship
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosure: Dr. Charles Shapiro has no relevant financial relationships with commercial interests to disclose.

Jenny Chang, MD
Director, Methodist Cancer Center
The Methodist Hospital
Houston, TX
 
 

Disclosure: Dr. Jenny Chang has no relevant financial relationships with commercial interests to disclose.

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
 
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By